KB-1266

REGN5678-PSMA-hIgG4-S228P

Background

REGN5678 is a human IgG4-based, first-in-class costimulatory bsAb designed to target prostate tumors by bridging prostate specific membrane antigen expressing tumor cells with the costimulatory receptor, CD28, on T cells, and providing amplified T-cell receptor-CD3 complex-mediated T-cell activation within the tumor through the activation of CD28 signaling. At the tumor site, REGN5678 may synergize with PD-1 inhibitors, similar to cemiplimab. In mouse models, REGN5678 in combination with PD-1 antibody has improved anti-tumor activity compared with either therapy alone. By engaging previously activated T-cells that express CD28, REGN5678 may exhibit less toxicity than CD3 directed bi-specifics.

Specifications

Catalog Number:
KB-1266
Cell Line Name:
REGN5678-PSMA-hIgG4-S228P
Price:
0
Host Cell Line:
EXPI-CHO
Target:
PSMA
Species Reactivity:
Human
Application:
ELISA
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | ELISA

References

1.Charles G.Drake, Jingsong Zhang, Mark N.Stein, et al. A phase I/II study of REGN5678 (Anti-PSMAxCD28, a costimulatory bispecific antibody) with cemiplimab (anti-PD-1) in patients with metastatic castration-resistant prostate cancer from the Journal of Clinical Oncology. Journal of Clinical Oncology 2020; 2.Nichole Tucker. REGN5678 Plus Cemiplimab Shows Early, Dose-Dependent Efficacy in mCRPC. Targeted Oncology, Aug 4, 2022.
Please enable JavaScript in your browser to complete this form.